{"gene":"PLCB3","run_date":"2026-06-10T06:43:35","timeline":{"discoveries":[{"year":2011,"finding":"PLC-β3 constitutively interacts with FcεRI, Lyn, and SHP-1 in mast cells. PLC-β3 recruits SHP-1 to dephosphorylate Lyn at Tyr396, thereby suppressing Lyn activity and enabling downstream MAPK activation required for cytokine production. Loss of PLCB3 phenocopies SHP-1 mutant mast cells: reduced cytokine production but normal degranulation after FcεRI stimulation.","method":"Co-immunoprecipitation (constitutive complex), Plcb3-/- mouse phenotype, comparison with SHP-1 mutant mast cells, genetic epistasis","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP establishing complex, loss-of-function mouse with defined cellular phenotype, epistasis with SHP-1 mutant, multiple orthogonal methods in a focused mechanistic study","pmids":["21683628"],"is_preprint":false},{"year":2014,"finding":"PLC-β3 negatively regulates mast cell STAT5 activity and positively regulates SHP-1 activity in the skin. Plcb3-/- mice show increased STAT5 and reduced SHP-1 activities in mast cells, leading to spontaneous AD-like skin lesions. PLC-β3 also regulates periostin expression in fibroblasts and TSLP expression in keratinocytes.","method":"Plcb3-/- mouse model, mast cell-specific Stat5 and Shp1 conditional knockouts, immunohistochemistry, Western blotting","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple conditional knockouts with defined phenotypic readouts in a focused mechanistic study, multiple orthogonal methods","pmids":["24412367"],"is_preprint":false},{"year":2011,"finding":"PLCB3 mediates extracellular nucleotide-dependent intracellular calcium signaling in CF bronchial epithelial cells, leading to activation of protein kinase Cα and Cβ and NF-κB p65, which potentiates Toll-like receptor signaling and IL-8 release upon Pseudomonas aeruginosa exposure.","method":"PLCB3 silencing (shRNA) in bronchial epithelial cells, calcium signaling assays, PKC activity assays, NF-κB reporter, IL-8 ELISA","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function with defined signaling readouts in a single lab, multiple downstream pathway measurements","pmids":["21411730"],"is_preprint":false},{"year":2018,"finding":"The PLCB3-S845L variant (loss-of-function) shows defects in: (1) agonist-induced Ca2+ release from endoplasmic reticulum, (2) activation of conventional PKCβ, and (3) IL-8 release in CF bronchial epithelial cells. Synthetic catalytically-inactive mutants confirmed that enzymatic activity is required for these downstream signaling events.","method":"Expression of S845L variant and catalytic-dead mutants in CF bronchial epithelial cells, intracellular Ca2+ measurements, PKC activity assays, IL-8 ELISA, P. aeruginosa stimulation","journal":"American journal of respiratory cell and molecular biology","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — active-site/variant mutagenesis with functional readouts (Ca2+ release, PKC activation, cytokine secretion), single lab with multiple orthogonal methods","pmids":["29668297"],"is_preprint":false},{"year":2008,"finding":"PLCB3 serine-1105 (S1105) is phosphorylated by multiple kinases in human myometrial cells: PKA (via cAMP/PRKA pathway) and PKC (via oxytocin/Gq pathway). CPT-cAMP-mediated inhibition of oxytocin-stimulated phosphatidylinositol turnover requires S1105, as the S1105A mutant abolishes this negative cross-talk. Different protein phosphatases (PP2B for cAMP pathway; PP1/PP2A for oxytocin pathway) mediate S1105 dephosphorylation. PLCB3 shRNA significantly attenuated oxytocin-stimulated intracellular calcium increases.","method":"Phospho-S1105 antibody, PKA/PKC inhibitors, phosphatase inhibitors, PLCB3 shRNA knockdown, overexpression of WT and S1105A mutant PLCB3, phosphatidylinositol turnover assay, intracellular Ca2+ measurement","journal":"Biology of reproduction","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — site-directed mutagenesis (S1105A) combined with pharmacological dissection and shRNA knockdown with defined functional readouts, multiple orthogonal methods in one focused study","pmids":["18322273"],"is_preprint":false},{"year":2011,"finding":"PLCB3 is specifically up-regulated in granulosa cells from ovulatory-size follicles and localizes predominantly to the cytoplasm in these cells. RNA interference-mediated PLCB3 knockdown reduced LH-induced transcriptional up-regulation of prostaglandin-endoperoxide synthase 2, reduced aromatase expression, and reduced estradiol production, without affecting cAMP responses to LH, indicating PLCB3 mediates LH signaling through the Gq/PLC pathway rather than the Gs/AC/cAMP pathway.","method":"Expression analysis (mRNA and protein) across follicle sizes, immunofluorescence localization, RNA interference knockdown, inositol phosphate assay, prostaglandin synthase 2 mRNA assay, estradiol ELISA, cAMP assay","journal":"Endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RNAi loss-of-function with multiple defined differentiation readouts, localization by immunofluorescence, single lab with multiple orthogonal methods","pmids":["21586561"],"is_preprint":false},{"year":2017,"finding":"A homozygous missense variant (c.2632G>T; p.A878S) in PLCB3 disrupts binding of the Ha2' element to the catalytic core, destabilizing PLCB3. This hypomorphic variant leads to elevated PIP2 levels in patient fibroblasts and disorganization of the F-actin cytoskeleton, causing spondylometaphyseal dysplasia with corneal dystrophy.","method":"Whole exome sequencing, homozygosity mapping, PIP2 measurement in patient fibroblasts, F-actin immunofluorescence, structural domain analysis","journal":"Journal of medical genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — human genetics combined with functional validation in patient fibroblasts (PIP2 accumulation, actin cytoskeleton), single study with multiple methods","pmids":["29122926"],"is_preprint":false},{"year":2006,"finding":"In cat esophageal smooth muscle cells, S1P-induced contraction is mediated via PLCβ3. Introduction of PLCβ3 antibody into permeabilized cells inhibited S1P-induced contraction. The PLCβ3 activation leads to PKCε activation and subsequent p44/p42 MAPK pathway activation, downstream of S1P2 receptor coupled to Gi2, Gq, and Gβ proteins.","method":"Antibody microinjection into permeabilized smooth muscle cells, PLC inhibitor (U73122), PKC inhibitors, MEK inhibitor, contractility assay","journal":"Molecules and cells","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — intracellular antibody inhibition with contractility readout, multiple pharmacological inhibitors delineating pathway, single lab","pmids":["16511346"],"is_preprint":false},{"year":1999,"finding":"Transfection of PLCB3 into neuroendocrine tumor cell lines with low endogenous PLCB3 expression caused significant in vitro growth inhibition and reduced tumorigenicity in vivo (reduced tumor weight and Ki-67-positive proliferating cells in xenografts), indicating a tumor-suppressive role.","method":"PLCB3 transfection into neuroendocrine cell lines, [3H]thymidine incorporation, cell counting, nude mouse xenograft, Ki-67 immunostaining","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain-of-function in vitro and in vivo with defined proliferation phenotype, replicated across multiple cell lines","pmids":["10359076"],"is_preprint":false},{"year":2001,"finding":"PLCB3 transfection into BON-1 neuroendocrine tumor cells activates hMSH3 (mismatch repair protein 3) and a TIS/MA-3 homolog, while inhibiting S100A3 and Chromogranin A expression, indicating PLCB3-induced tumor suppression involves downstream transcriptional changes in DNA repair and apoptosis-related genes.","method":"RT-Differential cDNA Display of PLCB3-transfected vs. control BON-1 cells","journal":"Biochemical and biophysical research communications","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single method (differential display), single lab, no mechanistic follow-up of identified genes","pmids":["11178984"],"is_preprint":false},{"year":2024,"finding":"OSBPL2 directly interacts with PLCB3 and inhibits PLCB3 ubiquitylation, thereby stabilizing PLCB3 protein. Loss-of-function OSBPL2 variants lead to enhanced ubiquitination and degradation of PLCB3, causing epidermal hyperkeratosis with aberrant keratinocyte proliferation and delayed terminal differentiation.","method":"Co-immunoprecipitation (direct interaction), ubiquitylation assay, exome sequencing, cell-based keratinocyte differentiation assays","journal":"Biochimica et biophysica acta. Molecular basis of disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP establishing direct interaction, ubiquitylation assay identifying OSBPL2 as a stabilizer, functional keratinocyte phenotype, single lab","pmids":["38701954"],"is_preprint":false},{"year":1995,"finding":"The human PLCB3 gene contains 31 exons spanning ~15 kb on chromosome 11q13, encodes a 1234 amino acid protein, produces a single 4.4 kb transcript ubiquitously expressed, and has a GC-rich housekeeping promoter with multiple Sp1 sites but lacking TATA and CAAT boxes. The transcription initiation site was mapped 328-321 bp upstream of the translation start.","method":"cDNA cloning, genomic sequencing, Northern blotting, primer extension/transcription initiation mapping","journal":"Genomics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct genomic sequencing and Northern blotting with transcription start site mapping, foundational structural characterization","pmids":["7607669"],"is_preprint":false},{"year":2022,"finding":"Exosomal miR-24-3p from human umbilical cord mesenchymal stem cells suppresses Plcb3 expression in macrophages, leading to reduced NF-κB pathway activation and promotion of M2 macrophage polarization. Knockdown of miR-24-3p in exosomes attenuated M2 polarization, while increasing miR-24-3p in macrophages enhanced M2 polarization by suppressing Plcb3.","method":"RNA sequencing, miRNA transfection, Plcb3 knockdown, NF-κB reporter/Western blot, macrophage polarization markers, in vivo myocardial infarction model","journal":"Advanced biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — miRNA gain/loss-of-function combined with Plcb3 knockdown and NF-κB pathway readout, single lab with multiple methods","pmids":["35818695"],"is_preprint":false},{"year":2024,"finding":"PLCB3 knockdown inhibited colorectal cancer cell proliferation, migration, and invasion. Cetuximab treatment reduced both β-catenin and PLCB3 expression while augmenting E-cadherin expression; simultaneous application of a Wnt activator with PLCB3 reversed cetuximab-mediated inhibition, placing PLCB3 downstream of EGFR and upstream of Wnt/β-catenin signaling in CRC.","method":"PLCB3 knockdown in CRC cell lines, cetuximab treatment, β-catenin/E-cadherin Western blotting, Wnt activator (IM12) rescue experiments, proliferation/migration/invasion assays","journal":"Scientific reports","confidence":"Low","confidence_rationale":"Tier 3 / Weak — loss-of-function with cell-based phenotype, pathway placement by pharmacological rescue, single lab without mechanistic depth","pmids":["38724565"],"is_preprint":false},{"year":2024,"finding":"PLCB3 is expressed in the cerebellar cortex (Purkinje cells) and deep nuclei of rhesus macaque monkeys, showing striped compartmentalization in the vermis and intense signals throughout the hemisphere, with distinct zonal patterns in the fastigial and dentate nuclei, indicating a conserved role in cerebellar molecular organization.","method":"Immunohistochemistry, immunofluorescence in non-human primate cerebellar tissue sections","journal":"The Journal of comparative neurology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — localization by immunohistochemistry without functional consequence established, single study","pmids":["39439015"],"is_preprint":false}],"current_model":"PLCB3 encodes phospholipase C-β3, which catalyzes hydrolysis of PIP2 to generate IP3 and DAG, thereby mobilizing intracellular Ca2+ and activating PKC isoforms; it operates downstream of Gq-coupled receptors (including FcεRI, LH receptor, S1P2, oxytocin receptor, and P2 receptors) and negatively regulates mast cell activation by constitutively recruiting SHP-1 to suppress Lyn kinase activity, while its catalytic activity at S845 and phosphorylation at S1105 integrate multiple kinase inputs (PKA, PKC) and phosphatase (PP2B, PP1/PP2A) signals; OSBPL2 stabilizes PLCB3 by inhibiting its ubiquitylation, and loss-of-function variants cause PIP2 accumulation, F-actin disorganization, and skeletal/epidermal dysplasias, while reduced PLCB3 activity attenuates NF-κB-driven IL-8 secretion and promotes M2 macrophage polarization."},"narrative":{"mechanistic_narrative":"PLCB3 encodes phospholipase C-β3, a Gq-coupled effector that hydrolyzes PIP2 to mobilize intracellular Ca2+ and activate PKC isoforms, thereby transducing diverse receptor signals into downstream transcriptional and cytoskeletal outputs [PMID:29668297, PMID:18322273]. Its catalytic activity—dependent on an intact active site (S845) and the Ha2' regulatory element that docks onto the catalytic core—drives agonist-induced ER Ca2+ release and conventional PKC activation; variants that impair catalysis or destabilize the protein cause PIP2 accumulation and F-actin disorganization, manifesting as spondylometaphyseal dysplasia with corneal dystrophy [PMID:29668297, PMID:29122926]. PLCB3 acts downstream of multiple Gq-coupled receptors, including the LH receptor in granulosa cells where it mediates LH-induced steroidogenic gene expression via the Gq/PLC arm rather than the Gs/cAMP arm [PMID:21586561], the S1P2 receptor in smooth muscle where it drives PKCε–MAPK contraction [PMID:16511346], and the oxytocin receptor in myometrium, where its serine-1105 phosphorylation integrates antagonistic PKA (cAMP) and PKC (Gq) inputs through distinct phosphatases (PP2B versus PP1/PP2A) to gate phosphatidylinositol turnover and Ca2+ flux [PMID:18322273]. Beyond catalysis, PLCB3 serves a scaffolding role in mast cells, where it constitutively assembles with FcεRI, Lyn, and SHP-1 and recruits SHP-1 to dephosphorylate Lyn at Tyr396, restraining mast cell activation and STAT5 signaling; its loss yields atopic-dermatitis-like skin pathology [PMID:21683628, PMID:24412367]. In epithelial and immune contexts PLCB3-driven PKC/NF-κB signaling potentiates IL-8 release and inflammatory responses [PMID:21411730, PMID:29668297]. PLCB3 protein stability is governed by OSBPL2, which binds PLCB3 and blocks its ubiquitylation; loss of this protection enhances PLCB3 degradation and causes epidermal hyperkeratosis [PMID:38701954].","teleology":[{"year":1995,"claim":"Establishing the gene architecture and expression pattern was the necessary foundation, defining PLCB3 as a ubiquitously expressed housekeeping gene encoding a 1234-residue protein.","evidence":"cDNA cloning, genomic sequencing, Northern blotting and transcription start mapping","pmids":["7607669"],"confidence":"Medium","gaps":["No functional or signaling role defined","Tissue-specific regulation not addressed"]},{"year":1999,"claim":"The first functional assignment came from gain-of-function in neuroendocrine tumor cells, indicating PLCB3 can restrain proliferation and tumorigenicity.","evidence":"PLCB3 transfection, thymidine incorporation, nude mouse xenografts with Ki-67 staining","pmids":["10359076"],"confidence":"Medium","gaps":["Catalytic requirement not tested","Mechanism of growth suppression unresolved"]},{"year":2001,"claim":"An attempt to link PLCB3 tumor suppression to transcriptional targets nominated DNA-repair and apoptosis-related genes, but only descriptively.","evidence":"RT-differential cDNA display in PLCB3-transfected BON-1 cells","pmids":["11178984"],"confidence":"Low","gaps":["Single descriptive method without validation","No mechanistic follow-up of nominated genes","No causal link to phenotype"]},{"year":2006,"claim":"Defining PLCB3 as the obligate effector for a specific GPCR established its role in receptor-driven contraction.","evidence":"Anti-PLCβ3 antibody microinjection into permeabilized smooth muscle cells with pharmacological pathway dissection and contractility assay","pmids":["16511346"],"confidence":"Medium","gaps":["Direct receptor coupling not biochemically resolved","Antibody inhibition not paralleled by genetic loss"]},{"year":2008,"claim":"Identification of S1105 as a convergence point for PKA and PKC phosphorylation explained how PLCB3 integrates antagonistic signaling inputs.","evidence":"Phospho-S1105 antibody, S1105A mutagenesis, kinase/phosphatase inhibitors, shRNA and PI-turnover/Ca2+ readouts in myometrial cells","pmids":["18322273"],"confidence":"High","gaps":["Structural basis of S1105-mediated regulation unknown","Whether S1105 directly alters catalytic rate not resolved"]},{"year":2011,"claim":"The discovery that PLCB3 constitutively scaffolds FcεRI, Lyn, and SHP-1 revealed a catalysis-independent, inhibitory signaling function in mast cells.","evidence":"Reciprocal Co-IP, Plcb3-/- mast cell phenotype, epistasis with SHP-1 mutant","pmids":["21683628"],"confidence":"High","gaps":["Whether scaffolding requires lipase activity not determined","Structural basis of SHP-1 recruitment unknown"]},{"year":2011,"claim":"Parallel work assigned PLCB3 to specific Gq pathways: LH-driven granulosa steroidogenesis and nucleotide-driven epithelial inflammation.","evidence":"RNAi knockdown with steroidogenic readouts in granulosa cells; shRNA with Ca2+/PKC/NF-κB/IL-8 readouts in CF bronchial epithelial cells","pmids":["21586561","21411730"],"confidence":"Medium","gaps":["Receptor-effector coupling not biochemically resolved","Catalytic dependence of IL-8 output not yet tested at this stage"]},{"year":2014,"claim":"Whole-organism analysis tied PLCB3 loss to dysregulated STAT5/SHP-1 balance and an atopic-dermatitis-like skin phenotype, extending the mast cell scaffolding role to disease.","evidence":"Plcb3-/- mice, mast cell-specific Stat5 and Shp1 conditional knockouts, IHC and Western blot","pmids":["24412367"],"confidence":"High","gaps":["Direct PLCB3 regulation of STAT5 not biochemically defined","Crosstalk with keratinocyte/fibroblast signals incompletely mapped"]},{"year":2017,"claim":"A human Mendelian variant established catalytic/structural integrity as essential, linking PLCB3 destabilization to PIP2 accumulation, actin disorganization, and skeletal/corneal disease.","evidence":"Exome sequencing, homozygosity mapping, PIP2 measurement and F-actin imaging in patient fibroblasts, structural domain analysis","pmids":["29122926"],"confidence":"Medium","gaps":["Mechanism linking PIP2 accumulation to actin disorganization not detailed","Tissue specificity of phenotype unexplained"]},{"year":2018,"claim":"Variant and catalytic-dead mutagenesis confirmed that enzymatic activity (S845) is required for Ca2+ release, PKCβ activation, and IL-8 secretion.","evidence":"Expression of S845L and catalytic-dead mutants in CF bronchial epithelial cells with Ca2+, PKC, and IL-8 readouts","pmids":["29668297"],"confidence":"Medium","gaps":["Structural impact of S845L not resolved","In vivo relevance to CF inflammation not established"]},{"year":2024,"claim":"Identification of OSBPL2 as a direct binder that blocks PLCB3 ubiquitylation revealed the post-translational control of PLCB3 abundance and its link to epidermal disease.","evidence":"Co-IP, ubiquitylation assay, exome sequencing, keratinocyte differentiation assays","pmids":["38701954"],"confidence":"Medium","gaps":["E3 ligase targeting PLCB3 not identified","Whether stabilized PLCB3 acts catalytically or as scaffold in keratinocytes unknown"]},{"year":2024,"claim":"Additional contexts placed PLCB3 in NF-κB-dependent macrophage polarization and EGFR/Wnt signaling in cancer, broadening but not deepening its mechanistic role.","evidence":"Exosomal miR-24-3p with Plcb3 knockdown and NF-κB readout in macrophages/MI model; PLCB3 knockdown with cetuximab and Wnt-activator rescue in CRC cells","pmids":["35818695","38724565"],"confidence":"Medium","gaps":["Direct molecular links to NF-κB and Wnt not biochemically defined","CRC pathway placement rests on pharmacological rescue only"]},{"year":2024,"claim":"Mapping PLCB3 to cerebellar Purkinje cells and deep nuclei suggested a compartmentalized neural role.","evidence":"Immunohistochemistry/immunofluorescence in macaque cerebellum","pmids":["39439015"],"confidence":"Low","gaps":["No functional consequence established","Localization only, single study"]},{"year":null,"claim":"How PLCB3's catalytic (lipase) and non-catalytic (SHP-1/Lyn scaffolding) functions are partitioned across cell types, and the structural determinants of its regulation by phosphorylation and ubiquitylation, remain open.","evidence":"","pmids":[],"confidence":"Low","gaps":["No structure of full-length PLCB3 or its regulatory complexes","E3 ligase and detailed degradation pathway unidentified","Lipase-dependence of scaffolding functions untested"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[3,4,6]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[3,6]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[5,7]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[0]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[5]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[4,5,7]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,1,2]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[6,10]}],"complexes":["FcεRI–Lyn–SHP-1 complex"],"partners":["FCER1A","LYN","PTPN6","OSBPL2"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q01970","full_name":"1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-3","aliases":["Phosphoinositide phospholipase C-beta-3","Phospholipase C-beta-3","PLC-beta-3"],"length_aa":1234,"mass_kda":138.8,"function":"Catalyzes the production of the second messenger molecules diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) (PubMed:20966218, PubMed:29122926, PubMed:37991948, PubMed:9188725). Key transducer of G protein-coupled receptor signaling: activated by G(q)/G(11) G alpha proteins downstream of G protein-coupled receptors activation (PubMed:20966218, PubMed:37991948). In neutrophils, participates in a phospholipase C-activating N-formyl peptide-activated GPCR (G protein-coupled receptor) signaling pathway by promoting RASGRP4 activation by DAG, to promote neutrophil functional responses (By similarity)","subcellular_location":"Cytoplasm; Membrane; Nucleus","url":"https://www.uniprot.org/uniprotkb/Q01970/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/PLCB3","classification":"Not Classified","n_dependent_lines":24,"n_total_lines":1208,"dependency_fraction":0.019867549668874173},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/PLCB3","total_profiled":1310},"omim":[{"mim_id":"618961","title":"SPONDYLOMETAPHYSEAL DYSPLASIA WITH CORNEAL DYSTROPHY; SMDCD","url":"https://www.omim.org/entry/618961"},{"mim_id":"615706","title":"AURICULOCONDYLAR SYNDROME 3; ARCND3","url":"https://www.omim.org/entry/615706"},{"mim_id":"612798","title":"QUESTION MARK EARS, ISOLATED; QME","url":"https://www.omim.org/entry/612798"},{"mim_id":"608455","title":"GLYCOGEN PHOSPHORYLASE, MUSCLE; PYGM","url":"https://www.omim.org/entry/608455"},{"mim_id":"607811","title":"p21-ACTIVATED KINASE- AND PHOSPHOLIPASE C-INTERACTING PROTEIN 1; PAK1IP1","url":"https://www.omim.org/entry/607811"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Golgi apparatus","reliability":"Supported"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"intestine","ntpm":107.1}],"url":"https://www.proteinatlas.org/search/PLCB3"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"Q01970","domains":[{"cath_id":"2.30.29.240","chopping":"21-221","consensus_level":"medium","plddt":93.51,"start":21,"end":221},{"cath_id":"1.10.238.10","chopping":"225-302","consensus_level":"high","plddt":94.0433,"start":225,"end":302},{"cath_id":"3.20.20.190","chopping":"327-472_576-706","consensus_level":"medium","plddt":95.7491,"start":327,"end":706},{"cath_id":"2.60.40.150","chopping":"727-857","consensus_level":"high","plddt":96.4885,"start":727,"end":857},{"cath_id":"1.20.1230.10","chopping":"957-997_1032-1077_1149-1193","consensus_level":"medium","plddt":90.3177,"start":957,"end":1193}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q01970","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q01970-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q01970-F1-predicted_aligned_error_v6.png","plddt_mean":82.31},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PLCB3","jax_strain_url":"https://www.jax.org/strain/search?query=PLCB3"},"sequence":{"accession":"Q01970","fasta_url":"https://rest.uniprot.org/uniprotkb/Q01970.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q01970/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q01970"}},"corpus_meta":[{"pmid":"26029847","id":"PMC_26029847","title":"The PRKAA1/AMPKα1 pathway triggers autophagy during CSF1-induced human monocyte differentiation and is a potential target in CMML.","date":"2015","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/26029847","citation_count":88,"is_preprint":false},{"pmid":"24412367","id":"PMC_24412367","title":"Critical role for mast cell Stat5 activity in skin inflammation.","date":"2014","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/24412367","citation_count":76,"is_preprint":false},{"pmid":"27191743","id":"PMC_27191743","title":"CAPE suppresses migration and invasion of prostate cancer cells via activation of non-canonical Wnt signaling.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27191743","citation_count":44,"is_preprint":false},{"pmid":"24096177","id":"PMC_24096177","title":"Contribution of genetic and epigenetic mechanisms to Wnt pathway activity in prevalent skeletal disorders.","date":"2013","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/24096177","citation_count":39,"is_preprint":false},{"pmid":"21411730","id":"PMC_21411730","title":"Phospholipase C-β3 is a key modulator of IL-8 expression in cystic fibrosis bronchial epithelial cells.","date":"2011","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/21411730","citation_count":39,"is_preprint":false},{"pmid":"21683628","id":"PMC_21683628","title":"Phospholipase C-β3 regulates FcɛRI-mediated mast cell activation by recruiting the protein phosphatase SHP-1.","date":"2011","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/21683628","citation_count":35,"is_preprint":false},{"pmid":"28453527","id":"PMC_28453527","title":"Altered nucleocytoplasmic proteome and transcriptome distributions in an in vitro model of amyotrophic lateral sclerosis.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/28453527","citation_count":32,"is_preprint":false},{"pmid":"26308735","id":"PMC_26308735","title":"Pathway Analysis Based on a Genome-Wide Association Study of Polycystic Ovary Syndrome.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26308735","citation_count":32,"is_preprint":false},{"pmid":"35818695","id":"PMC_35818695","title":"Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes Attenuate Myocardial Infarction Injury via miR-24-3p-Promoted M2 Macrophage Polarization.","date":"2022","source":"Advanced biology","url":"https://pubmed.ncbi.nlm.nih.gov/35818695","citation_count":29,"is_preprint":false},{"pmid":"9286704","id":"PMC_9286704","title":"Construction of a 1.2-Mb sequence-ready contig of chromosome 11q13 encompassing the multiple endocrine neoplasia type 1 (MEN1) gene. The European Consortium on MEN1.","date":"1997","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/9286704","citation_count":28,"is_preprint":false},{"pmid":"8838322","id":"PMC_8838322","title":"Isolation and characterization of a novel gene close to the human phosphoinositide-specific phospholipase C beta 3 gene on chromosomal region 11q13.","date":"1996","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/8838322","citation_count":24,"is_preprint":false},{"pmid":"7607669","id":"PMC_7607669","title":"Genomic organization and complete cDNA sequence of the human phosphoinositide-specific phospholipase C beta 3 gene (PLCB3).","date":"1995","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/7607669","citation_count":21,"is_preprint":false},{"pmid":"25219847","id":"PMC_25219847","title":"Ovarian superstimulation using FSH combined with equine chorionic gonadotropin (eCG) upregulates mRNA-encoding proteins involved with LH receptor intracellular signaling in granulosa cells from Nelore cows.","date":"2014","source":"Theriogenology","url":"https://pubmed.ncbi.nlm.nih.gov/25219847","citation_count":17,"is_preprint":false},{"pmid":"16511346","id":"PMC_16511346","title":"Sphingosine 1-phosphate-induced signal transduction in cat esophagus smooth muscle cells.","date":"2006","source":"Molecules and cells","url":"https://pubmed.ncbi.nlm.nih.gov/16511346","citation_count":16,"is_preprint":false},{"pmid":"18322273","id":"PMC_18322273","title":"Multiple signals regulate phospholipase CBeta3 in human myometrial cells.","date":"2008","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/18322273","citation_count":15,"is_preprint":false},{"pmid":"11178984","id":"PMC_11178984","title":"Differentially expressed cDNAs in PLCbeta3-induced tumor suppression in a human endocrine pancreatic tumor cell line: activation of the human mismatch repair protein 3 gene.","date":"2001","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/11178984","citation_count":15,"is_preprint":false},{"pmid":"29668297","id":"PMC_29668297","title":"PLCB3 Loss of Function Reduces Pseudomonas aeruginosa-Dependent IL-8 Release in Cystic Fibrosis.","date":"2018","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/29668297","citation_count":14,"is_preprint":false},{"pmid":"21586561","id":"PMC_21586561","title":"Phospholipase Cβ3 mediates LH-induced granulosa cell differentiation.","date":"2011","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/21586561","citation_count":14,"is_preprint":false},{"pmid":"33405298","id":"PMC_33405298","title":"iTRAQ-based proteomic analysis of the molecular mechanisms and downstream effects of fatty acid synthase in osteosarcoma cells.","date":"2021","source":"Journal of clinical laboratory analysis","url":"https://pubmed.ncbi.nlm.nih.gov/33405298","citation_count":14,"is_preprint":false},{"pmid":"25753874","id":"PMC_25753874","title":"Effect evaluation of cisplatin-gemcitabine combination chemotherapy for advanced non-small cell lung cancer patients using microarray data.","date":"2015","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/25753874","citation_count":13,"is_preprint":false},{"pmid":"9003510","id":"PMC_9003510","title":"Exclusion of the phosphoinositide-specific phospholipase C beta 3 (PLCB3) gene as a candidate for multiple endocrine neoplasia type 1.","date":"1997","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9003510","citation_count":11,"is_preprint":false},{"pmid":"10359076","id":"PMC_10359076","title":"Suppression of the neoplastic phenotype by transfection of phospholipase C beta 3 to neuroendocrine tumor cells.","date":"1999","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/10359076","citation_count":10,"is_preprint":false},{"pmid":"38954658","id":"PMC_38954658","title":"Tibial cortex transverse transport surgery improves wound healing in patients with severe type 2 DFUs by activating a systemic immune response: a cross-sectional study.","date":"2025","source":"International journal of surgery (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/38954658","citation_count":10,"is_preprint":false},{"pmid":"7789993","id":"PMC_7789993","title":"Localization of the human phosphatidylinositol-specific phospholipase c beta 3 gene (PLCB3) within chromosome band 11q13.","date":"1995","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/7789993","citation_count":9,"is_preprint":false},{"pmid":"35156189","id":"PMC_35156189","title":"Insulin-like growth factor-1 inhibits apoptosis of rat gastric smooth muscle cells under high glucose condition via adenosine monophosphate-activated protein kinase (AMPK) pathway.","date":"2022","source":"Folia histochemica et cytobiologica","url":"https://pubmed.ncbi.nlm.nih.gov/35156189","citation_count":9,"is_preprint":false},{"pmid":"35942506","id":"PMC_35942506","title":"The genetic architecture of blood pressure variability: A genome-wide association study of 9370 participants from UK Biobank.","date":"2022","source":"Journal of clinical hypertension (Greenwich, Conn.)","url":"https://pubmed.ncbi.nlm.nih.gov/35942506","citation_count":9,"is_preprint":false},{"pmid":"29122926","id":"PMC_29122926","title":"Defect in phosphoinositide signalling through a homozygous variant in PLCB3 causes a new form of spondylometaphyseal dysplasia with corneal dystrophy.","date":"2017","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/29122926","citation_count":8,"is_preprint":false},{"pmid":"12894496","id":"PMC_12894496","title":"In situ RNA-RNA hybridisation of phospholipase C beta 3 shows lack of expression in neuroendocrine tumours.","date":"2003","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/12894496","citation_count":8,"is_preprint":false},{"pmid":"12823437","id":"PMC_12823437","title":"The ichq mutant mouse, a model for the human skin disorder harlequin ichthyosis: mapping, keratinocyte culture, and consideration of candidate genes involved in epidermal growth regulation.","date":"2003","source":"Experimental dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/12823437","citation_count":7,"is_preprint":false},{"pmid":"31737645","id":"PMC_31737645","title":"Is MYND Domain-Mediated Assembly of SMYD3 Complexes Involved in Calcium Dependent Signaling?","date":"2019","source":"Frontiers in molecular biosciences","url":"https://pubmed.ncbi.nlm.nih.gov/31737645","citation_count":6,"is_preprint":false},{"pmid":"38405768","id":"PMC_38405768","title":"Fine-mapping genomic loci refines bipolar disorder risk genes.","date":"2024","source":"medRxiv : the preprint server for health sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38405768","citation_count":6,"is_preprint":false},{"pmid":"27122524","id":"PMC_27122524","title":"Expression of inflammation/pain-related genes in the dorsal root ganglion following disc puncture in rats.","date":"2016","source":"Journal of orthopaedic surgery (Hong Kong)","url":"https://pubmed.ncbi.nlm.nih.gov/27122524","citation_count":6,"is_preprint":false},{"pmid":"29725345","id":"PMC_29725345","title":"A Genome-Wide Linkage Study for Chronic Obstructive Pulmonary Disease in a Dutch Genetic Isolate Identifies Novel Rare Candidate Variants.","date":"2018","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/29725345","citation_count":5,"is_preprint":false},{"pmid":"7587389","id":"PMC_7587389","title":"Assignment of the mouse homologue of a human MEN1 candidate gene, phospholipase C-beta 3 (Plcb3), to chromosome region 19B by FISH.","date":"1995","source":"Cytogenetics and cell genetics","url":"https://pubmed.ncbi.nlm.nih.gov/7587389","citation_count":4,"is_preprint":false},{"pmid":"39802100","id":"PMC_39802100","title":"First Indonesian Nasopharyngeal Cancer Whole Epigenome Sequencing Identify Tumour Suppressor CpG Methylation.","date":"2025","source":"Biologics : targets & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/39802100","citation_count":4,"is_preprint":false},{"pmid":"38724565","id":"PMC_38724565","title":"Cetuximab inhibits colorectal cancer development through inactivating the Wnt/β-catenin pathway and modulating PLCB3 expression.","date":"2024","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/38724565","citation_count":3,"is_preprint":false},{"pmid":"37832654","id":"PMC_37832654","title":"Illuminating (HTLV-1)-induced adult T-cell leukemia/lymphoma transcriptomic signature: A systems virology approach.","date":"2023","source":"Virus research","url":"https://pubmed.ncbi.nlm.nih.gov/37832654","citation_count":3,"is_preprint":false},{"pmid":"39439015","id":"PMC_39439015","title":"Cerebellar Molecular Signatures in Non-Human Primates.","date":"2024","source":"The Journal of comparative neurology","url":"https://pubmed.ncbi.nlm.nih.gov/39439015","citation_count":0,"is_preprint":false},{"pmid":"40892863","id":"PMC_40892863","title":"Transcriptional profiling identification of inflammatory signaling pathways in ulcerative colitis.","date":"2025","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/40892863","citation_count":0,"is_preprint":false},{"pmid":"38701954","id":"PMC_38701954","title":"OSBPL2 compound heterozygous variants cause dyschromatosis, ichthyosis, deafness and atopic disease syndrome.","date":"2024","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/38701954","citation_count":0,"is_preprint":false},{"pmid":"37592823","id":"PMC_37592823","title":"Extension domain of amyloid processor protein inhibits amyloidogenic cleavage and balances neural activity in a traumatic brain injury mouse model.","date":"2023","source":"CNS neuroscience & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/37592823","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2024.09.17.24313718","title":"Exome wide association study for blood lipids in 1,158,017 individuals from diverse populations","date":"2024-09-18","source":"bioRxiv","url":"https://doi.org/10.1101/2024.09.17.24313718","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":24620,"output_tokens":4291,"usd":0.069112,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":12236,"output_tokens":4194,"usd":0.083015,"stage2_stop_reason":"end_turn"},"total_usd":0.152127,"stage1_batch_id":"msgbatch_01CNoDbkChHEkgrJnL7BwtGJ","stage2_batch_id":"msgbatch_016Y4x9E9Wg5VQDANj9quSQD","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2011,\n      \"finding\": \"PLC-β3 constitutively interacts with FcεRI, Lyn, and SHP-1 in mast cells. PLC-β3 recruits SHP-1 to dephosphorylate Lyn at Tyr396, thereby suppressing Lyn activity and enabling downstream MAPK activation required for cytokine production. Loss of PLCB3 phenocopies SHP-1 mutant mast cells: reduced cytokine production but normal degranulation after FcεRI stimulation.\",\n      \"method\": \"Co-immunoprecipitation (constitutive complex), Plcb3-/- mouse phenotype, comparison with SHP-1 mutant mast cells, genetic epistasis\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP establishing complex, loss-of-function mouse with defined cellular phenotype, epistasis with SHP-1 mutant, multiple orthogonal methods in a focused mechanistic study\",\n      \"pmids\": [\"21683628\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"PLC-β3 negatively regulates mast cell STAT5 activity and positively regulates SHP-1 activity in the skin. Plcb3-/- mice show increased STAT5 and reduced SHP-1 activities in mast cells, leading to spontaneous AD-like skin lesions. PLC-β3 also regulates periostin expression in fibroblasts and TSLP expression in keratinocytes.\",\n      \"method\": \"Plcb3-/- mouse model, mast cell-specific Stat5 and Shp1 conditional knockouts, immunohistochemistry, Western blotting\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple conditional knockouts with defined phenotypic readouts in a focused mechanistic study, multiple orthogonal methods\",\n      \"pmids\": [\"24412367\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"PLCB3 mediates extracellular nucleotide-dependent intracellular calcium signaling in CF bronchial epithelial cells, leading to activation of protein kinase Cα and Cβ and NF-κB p65, which potentiates Toll-like receptor signaling and IL-8 release upon Pseudomonas aeruginosa exposure.\",\n      \"method\": \"PLCB3 silencing (shRNA) in bronchial epithelial cells, calcium signaling assays, PKC activity assays, NF-κB reporter, IL-8 ELISA\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function with defined signaling readouts in a single lab, multiple downstream pathway measurements\",\n      \"pmids\": [\"21411730\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"The PLCB3-S845L variant (loss-of-function) shows defects in: (1) agonist-induced Ca2+ release from endoplasmic reticulum, (2) activation of conventional PKCβ, and (3) IL-8 release in CF bronchial epithelial cells. Synthetic catalytically-inactive mutants confirmed that enzymatic activity is required for these downstream signaling events.\",\n      \"method\": \"Expression of S845L variant and catalytic-dead mutants in CF bronchial epithelial cells, intracellular Ca2+ measurements, PKC activity assays, IL-8 ELISA, P. aeruginosa stimulation\",\n      \"journal\": \"American journal of respiratory cell and molecular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — active-site/variant mutagenesis with functional readouts (Ca2+ release, PKC activation, cytokine secretion), single lab with multiple orthogonal methods\",\n      \"pmids\": [\"29668297\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"PLCB3 serine-1105 (S1105) is phosphorylated by multiple kinases in human myometrial cells: PKA (via cAMP/PRKA pathway) and PKC (via oxytocin/Gq pathway). CPT-cAMP-mediated inhibition of oxytocin-stimulated phosphatidylinositol turnover requires S1105, as the S1105A mutant abolishes this negative cross-talk. Different protein phosphatases (PP2B for cAMP pathway; PP1/PP2A for oxytocin pathway) mediate S1105 dephosphorylation. PLCB3 shRNA significantly attenuated oxytocin-stimulated intracellular calcium increases.\",\n      \"method\": \"Phospho-S1105 antibody, PKA/PKC inhibitors, phosphatase inhibitors, PLCB3 shRNA knockdown, overexpression of WT and S1105A mutant PLCB3, phosphatidylinositol turnover assay, intracellular Ca2+ measurement\",\n      \"journal\": \"Biology of reproduction\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — site-directed mutagenesis (S1105A) combined with pharmacological dissection and shRNA knockdown with defined functional readouts, multiple orthogonal methods in one focused study\",\n      \"pmids\": [\"18322273\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"PLCB3 is specifically up-regulated in granulosa cells from ovulatory-size follicles and localizes predominantly to the cytoplasm in these cells. RNA interference-mediated PLCB3 knockdown reduced LH-induced transcriptional up-regulation of prostaglandin-endoperoxide synthase 2, reduced aromatase expression, and reduced estradiol production, without affecting cAMP responses to LH, indicating PLCB3 mediates LH signaling through the Gq/PLC pathway rather than the Gs/AC/cAMP pathway.\",\n      \"method\": \"Expression analysis (mRNA and protein) across follicle sizes, immunofluorescence localization, RNA interference knockdown, inositol phosphate assay, prostaglandin synthase 2 mRNA assay, estradiol ELISA, cAMP assay\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RNAi loss-of-function with multiple defined differentiation readouts, localization by immunofluorescence, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"21586561\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"A homozygous missense variant (c.2632G>T; p.A878S) in PLCB3 disrupts binding of the Ha2' element to the catalytic core, destabilizing PLCB3. This hypomorphic variant leads to elevated PIP2 levels in patient fibroblasts and disorganization of the F-actin cytoskeleton, causing spondylometaphyseal dysplasia with corneal dystrophy.\",\n      \"method\": \"Whole exome sequencing, homozygosity mapping, PIP2 measurement in patient fibroblasts, F-actin immunofluorescence, structural domain analysis\",\n      \"journal\": \"Journal of medical genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — human genetics combined with functional validation in patient fibroblasts (PIP2 accumulation, actin cytoskeleton), single study with multiple methods\",\n      \"pmids\": [\"29122926\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"In cat esophageal smooth muscle cells, S1P-induced contraction is mediated via PLCβ3. Introduction of PLCβ3 antibody into permeabilized cells inhibited S1P-induced contraction. The PLCβ3 activation leads to PKCε activation and subsequent p44/p42 MAPK pathway activation, downstream of S1P2 receptor coupled to Gi2, Gq, and Gβ proteins.\",\n      \"method\": \"Antibody microinjection into permeabilized smooth muscle cells, PLC inhibitor (U73122), PKC inhibitors, MEK inhibitor, contractility assay\",\n      \"journal\": \"Molecules and cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — intracellular antibody inhibition with contractility readout, multiple pharmacological inhibitors delineating pathway, single lab\",\n      \"pmids\": [\"16511346\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Transfection of PLCB3 into neuroendocrine tumor cell lines with low endogenous PLCB3 expression caused significant in vitro growth inhibition and reduced tumorigenicity in vivo (reduced tumor weight and Ki-67-positive proliferating cells in xenografts), indicating a tumor-suppressive role.\",\n      \"method\": \"PLCB3 transfection into neuroendocrine cell lines, [3H]thymidine incorporation, cell counting, nude mouse xenograft, Ki-67 immunostaining\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain-of-function in vitro and in vivo with defined proliferation phenotype, replicated across multiple cell lines\",\n      \"pmids\": [\"10359076\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"PLCB3 transfection into BON-1 neuroendocrine tumor cells activates hMSH3 (mismatch repair protein 3) and a TIS/MA-3 homolog, while inhibiting S100A3 and Chromogranin A expression, indicating PLCB3-induced tumor suppression involves downstream transcriptional changes in DNA repair and apoptosis-related genes.\",\n      \"method\": \"RT-Differential cDNA Display of PLCB3-transfected vs. control BON-1 cells\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single method (differential display), single lab, no mechanistic follow-up of identified genes\",\n      \"pmids\": [\"11178984\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"OSBPL2 directly interacts with PLCB3 and inhibits PLCB3 ubiquitylation, thereby stabilizing PLCB3 protein. Loss-of-function OSBPL2 variants lead to enhanced ubiquitination and degradation of PLCB3, causing epidermal hyperkeratosis with aberrant keratinocyte proliferation and delayed terminal differentiation.\",\n      \"method\": \"Co-immunoprecipitation (direct interaction), ubiquitylation assay, exome sequencing, cell-based keratinocyte differentiation assays\",\n      \"journal\": \"Biochimica et biophysica acta. Molecular basis of disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP establishing direct interaction, ubiquitylation assay identifying OSBPL2 as a stabilizer, functional keratinocyte phenotype, single lab\",\n      \"pmids\": [\"38701954\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"The human PLCB3 gene contains 31 exons spanning ~15 kb on chromosome 11q13, encodes a 1234 amino acid protein, produces a single 4.4 kb transcript ubiquitously expressed, and has a GC-rich housekeeping promoter with multiple Sp1 sites but lacking TATA and CAAT boxes. The transcription initiation site was mapped 328-321 bp upstream of the translation start.\",\n      \"method\": \"cDNA cloning, genomic sequencing, Northern blotting, primer extension/transcription initiation mapping\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct genomic sequencing and Northern blotting with transcription start site mapping, foundational structural characterization\",\n      \"pmids\": [\"7607669\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Exosomal miR-24-3p from human umbilical cord mesenchymal stem cells suppresses Plcb3 expression in macrophages, leading to reduced NF-κB pathway activation and promotion of M2 macrophage polarization. Knockdown of miR-24-3p in exosomes attenuated M2 polarization, while increasing miR-24-3p in macrophages enhanced M2 polarization by suppressing Plcb3.\",\n      \"method\": \"RNA sequencing, miRNA transfection, Plcb3 knockdown, NF-κB reporter/Western blot, macrophage polarization markers, in vivo myocardial infarction model\",\n      \"journal\": \"Advanced biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — miRNA gain/loss-of-function combined with Plcb3 knockdown and NF-κB pathway readout, single lab with multiple methods\",\n      \"pmids\": [\"35818695\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"PLCB3 knockdown inhibited colorectal cancer cell proliferation, migration, and invasion. Cetuximab treatment reduced both β-catenin and PLCB3 expression while augmenting E-cadherin expression; simultaneous application of a Wnt activator with PLCB3 reversed cetuximab-mediated inhibition, placing PLCB3 downstream of EGFR and upstream of Wnt/β-catenin signaling in CRC.\",\n      \"method\": \"PLCB3 knockdown in CRC cell lines, cetuximab treatment, β-catenin/E-cadherin Western blotting, Wnt activator (IM12) rescue experiments, proliferation/migration/invasion assays\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — loss-of-function with cell-based phenotype, pathway placement by pharmacological rescue, single lab without mechanistic depth\",\n      \"pmids\": [\"38724565\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"PLCB3 is expressed in the cerebellar cortex (Purkinje cells) and deep nuclei of rhesus macaque monkeys, showing striped compartmentalization in the vermis and intense signals throughout the hemisphere, with distinct zonal patterns in the fastigial and dentate nuclei, indicating a conserved role in cerebellar molecular organization.\",\n      \"method\": \"Immunohistochemistry, immunofluorescence in non-human primate cerebellar tissue sections\",\n      \"journal\": \"The Journal of comparative neurology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — localization by immunohistochemistry without functional consequence established, single study\",\n      \"pmids\": [\"39439015\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PLCB3 encodes phospholipase C-β3, which catalyzes hydrolysis of PIP2 to generate IP3 and DAG, thereby mobilizing intracellular Ca2+ and activating PKC isoforms; it operates downstream of Gq-coupled receptors (including FcεRI, LH receptor, S1P2, oxytocin receptor, and P2 receptors) and negatively regulates mast cell activation by constitutively recruiting SHP-1 to suppress Lyn kinase activity, while its catalytic activity at S845 and phosphorylation at S1105 integrate multiple kinase inputs (PKA, PKC) and phosphatase (PP2B, PP1/PP2A) signals; OSBPL2 stabilizes PLCB3 by inhibiting its ubiquitylation, and loss-of-function variants cause PIP2 accumulation, F-actin disorganization, and skeletal/epidermal dysplasias, while reduced PLCB3 activity attenuates NF-κB-driven IL-8 secretion and promotes M2 macrophage polarization.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"PLCB3 encodes phospholipase C-β3, a Gq-coupled effector that hydrolyzes PIP2 to mobilize intracellular Ca2+ and activate PKC isoforms, thereby transducing diverse receptor signals into downstream transcriptional and cytoskeletal outputs [#3, #4]. Its catalytic activity—dependent on an intact active site (S845) and the Ha2' regulatory element that docks onto the catalytic core—drives agonist-induced ER Ca2+ release and conventional PKC activation; variants that impair catalysis or destabilize the protein cause PIP2 accumulation and F-actin disorganization, manifesting as spondylometaphyseal dysplasia with corneal dystrophy [#3, #6]. PLCB3 acts downstream of multiple Gq-coupled receptors, including the LH receptor in granulosa cells where it mediates LH-induced steroidogenic gene expression via the Gq/PLC arm rather than the Gs/cAMP arm [#5], the S1P2 receptor in smooth muscle where it drives PKCε–MAPK contraction [#7], and the oxytocin receptor in myometrium, where its serine-1105 phosphorylation integrates antagonistic PKA (cAMP) and PKC (Gq) inputs through distinct phosphatases (PP2B versus PP1/PP2A) to gate phosphatidylinositol turnover and Ca2+ flux [#4]. Beyond catalysis, PLCB3 serves a scaffolding role in mast cells, where it constitutively assembles with FcεRI, Lyn, and SHP-1 and recruits SHP-1 to dephosphorylate Lyn at Tyr396, restraining mast cell activation and STAT5 signaling; its loss yields atopic-dermatitis-like skin pathology [#0, #1]. In epithelial and immune contexts PLCB3-driven PKC/NF-κB signaling potentiates IL-8 release and inflammatory responses [#2, #3]. PLCB3 protein stability is governed by OSBPL2, which binds PLCB3 and blocks its ubiquitylation; loss of this protection enhances PLCB3 degradation and causes epidermal hyperkeratosis [#10].\",\n  \"teleology\": [\n    {\n      \"year\": 1995,\n      \"claim\": \"Establishing the gene architecture and expression pattern was the necessary foundation, defining PLCB3 as a ubiquitously expressed housekeeping gene encoding a 1234-residue protein.\",\n      \"evidence\": \"cDNA cloning, genomic sequencing, Northern blotting and transcription start mapping\",\n      \"pmids\": [\"7607669\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No functional or signaling role defined\", \"Tissue-specific regulation not addressed\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"The first functional assignment came from gain-of-function in neuroendocrine tumor cells, indicating PLCB3 can restrain proliferation and tumorigenicity.\",\n      \"evidence\": \"PLCB3 transfection, thymidine incorporation, nude mouse xenografts with Ki-67 staining\",\n      \"pmids\": [\"10359076\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Catalytic requirement not tested\", \"Mechanism of growth suppression unresolved\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"An attempt to link PLCB3 tumor suppression to transcriptional targets nominated DNA-repair and apoptosis-related genes, but only descriptively.\",\n      \"evidence\": \"RT-differential cDNA display in PLCB3-transfected BON-1 cells\",\n      \"pmids\": [\"11178984\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Single descriptive method without validation\", \"No mechanistic follow-up of nominated genes\", \"No causal link to phenotype\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Defining PLCB3 as the obligate effector for a specific GPCR established its role in receptor-driven contraction.\",\n      \"evidence\": \"Anti-PLCβ3 antibody microinjection into permeabilized smooth muscle cells with pharmacological pathway dissection and contractility assay\",\n      \"pmids\": [\"16511346\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct receptor coupling not biochemically resolved\", \"Antibody inhibition not paralleled by genetic loss\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Identification of S1105 as a convergence point for PKA and PKC phosphorylation explained how PLCB3 integrates antagonistic signaling inputs.\",\n      \"evidence\": \"Phospho-S1105 antibody, S1105A mutagenesis, kinase/phosphatase inhibitors, shRNA and PI-turnover/Ca2+ readouts in myometrial cells\",\n      \"pmids\": [\"18322273\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of S1105-mediated regulation unknown\", \"Whether S1105 directly alters catalytic rate not resolved\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"The discovery that PLCB3 constitutively scaffolds FcεRI, Lyn, and SHP-1 revealed a catalysis-independent, inhibitory signaling function in mast cells.\",\n      \"evidence\": \"Reciprocal Co-IP, Plcb3-/- mast cell phenotype, epistasis with SHP-1 mutant\",\n      \"pmids\": [\"21683628\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether scaffolding requires lipase activity not determined\", \"Structural basis of SHP-1 recruitment unknown\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Parallel work assigned PLCB3 to specific Gq pathways: LH-driven granulosa steroidogenesis and nucleotide-driven epithelial inflammation.\",\n      \"evidence\": \"RNAi knockdown with steroidogenic readouts in granulosa cells; shRNA with Ca2+/PKC/NF-κB/IL-8 readouts in CF bronchial epithelial cells\",\n      \"pmids\": [\"21586561\", \"21411730\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor-effector coupling not biochemically resolved\", \"Catalytic dependence of IL-8 output not yet tested at this stage\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Whole-organism analysis tied PLCB3 loss to dysregulated STAT5/SHP-1 balance and an atopic-dermatitis-like skin phenotype, extending the mast cell scaffolding role to disease.\",\n      \"evidence\": \"Plcb3-/- mice, mast cell-specific Stat5 and Shp1 conditional knockouts, IHC and Western blot\",\n      \"pmids\": [\"24412367\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct PLCB3 regulation of STAT5 not biochemically defined\", \"Crosstalk with keratinocyte/fibroblast signals incompletely mapped\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"A human Mendelian variant established catalytic/structural integrity as essential, linking PLCB3 destabilization to PIP2 accumulation, actin disorganization, and skeletal/corneal disease.\",\n      \"evidence\": \"Exome sequencing, homozygosity mapping, PIP2 measurement and F-actin imaging in patient fibroblasts, structural domain analysis\",\n      \"pmids\": [\"29122926\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism linking PIP2 accumulation to actin disorganization not detailed\", \"Tissue specificity of phenotype unexplained\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Variant and catalytic-dead mutagenesis confirmed that enzymatic activity (S845) is required for Ca2+ release, PKCβ activation, and IL-8 secretion.\",\n      \"evidence\": \"Expression of S845L and catalytic-dead mutants in CF bronchial epithelial cells with Ca2+, PKC, and IL-8 readouts\",\n      \"pmids\": [\"29668297\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural impact of S845L not resolved\", \"In vivo relevance to CF inflammation not established\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identification of OSBPL2 as a direct binder that blocks PLCB3 ubiquitylation revealed the post-translational control of PLCB3 abundance and its link to epidermal disease.\",\n      \"evidence\": \"Co-IP, ubiquitylation assay, exome sequencing, keratinocyte differentiation assays\",\n      \"pmids\": [\"38701954\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"E3 ligase targeting PLCB3 not identified\", \"Whether stabilized PLCB3 acts catalytically or as scaffold in keratinocytes unknown\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Additional contexts placed PLCB3 in NF-κB-dependent macrophage polarization and EGFR/Wnt signaling in cancer, broadening but not deepening its mechanistic role.\",\n      \"evidence\": \"Exosomal miR-24-3p with Plcb3 knockdown and NF-κB readout in macrophages/MI model; PLCB3 knockdown with cetuximab and Wnt-activator rescue in CRC cells\",\n      \"pmids\": [\"35818695\", \"38724565\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct molecular links to NF-κB and Wnt not biochemically defined\", \"CRC pathway placement rests on pharmacological rescue only\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Mapping PLCB3 to cerebellar Purkinje cells and deep nuclei suggested a compartmentalized neural role.\",\n      \"evidence\": \"Immunohistochemistry/immunofluorescence in macaque cerebellum\",\n      \"pmids\": [\"39439015\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No functional consequence established\", \"Localization only, single study\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How PLCB3's catalytic (lipase) and non-catalytic (SHP-1/Lyn scaffolding) functions are partitioned across cell types, and the structural determinants of its regulation by phosphorylation and ubiquitylation, remain open.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No structure of full-length PLCB3 or its regulatory complexes\", \"E3 ligase and detailed degradation pathway unidentified\", \"Lipase-dependence of scaffolding functions untested\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [3, 4, 6]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [3, 6]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [5, 7]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [5]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [4, 5, 7]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 1, 2]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [6, 10]}\n    ],\n    \"complexes\": [\"FcεRI–Lyn–SHP-1 complex\"],\n    \"partners\": [\"FCER1A\", \"LYN\", \"PTPN6\", \"OSBPL2\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}